Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

HC Wainwright & Co. Maintains Buy on ADMA Biologics, Raises Price Target to $6

Author: Benzinga Newsdesk | January 09, 2024 08:09am
HC Wainwright & Co. analyst Raghuram Selvaraju maintains ADMA Biologics (NASDAQ:ADMA) with a Buy and raises the price target from $5 to $6.

Posted In: ADMA

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist